Literature DB >> 32201467

Immediate Results and Long-Term Outcomes Following Percutaneous Radiofrequency Ablation of Unilateral Aldosterone-Producing Adenoma.

Chien-Hsien Lo1, Yeu-Sheng Tyan2, Kwo-Chang Ueng1,3.   

Abstract

BACKGROUND: The aim of this study was to evaluate early and long-term clinical and laboratory findings in patients with resistant hypertension secondary to aldosterone-producing adenoma (APA) treated with radiofrequency ablation (RFA).
METHODS: From July 2009 to September 2017, eight adult patients underwent percutaneous computed tomography (CT)-guided RFA for APA. The safety, efficacy and complications of the procedure were determined. Blood pressure (BP), number of antihypertensive agents, serum potassium, plasma aldosterone and aldosterone-to-renin ratio (ARR) were analyzed before RFA and immediately, short-term and long-term after RFA.
RESULTS: The technical success rate was 100%. Two patients developed minor complications but there were no major complications. Clinical improvement was achieved immediately and short-term after RFA. In the long-term (mean follow-up duration of 6.7 ± 2.1 years) there were significant improvements in systolic (from 162.3 mmHg ± 18.6 to 125 mmHg ± 16.1, p = 0.02) and diastolic (from 96.3 mmHg ± 12.7 to 68.5 mmHg ± 6.3, p = 0.02) BP, with a significant reduction in the number of antihypertensive agents (from 3.33 ± 0.82 to 1.33 ± 1.21, p = 0.02). Hypokalemia improved significantly (serum potassium from 2.16 meq/L ± 0.22 to 4.34 meq/L ± 0.54, p = 0.04). Although the plasma aldosterone level decreased significantly, ARR did not (from 100.7 ± 124.4 to 28.7 ± 30.7 ng/dL-per-ng/mL/h, p = 0.13). Hypertension was cured in 33.3% of the patients, and the BP of all patients was more easily controlled regardless of the plasma aldosterone and renin status.
CONCLUSIONS: CT-guided percutaneous RFA appears to be effective and safe to treat patients with APA, with clinical improvements in BP, reduced number of antihypertensive agents, and normalization of serum potassium level. These favorable outcomes persisted in short-term and long-term follow-up.

Entities:  

Keywords:  Adrenal adenoma; Aldosterone; Hypertension; Radio-frequency ablation

Year:  2020        PMID: 32201467      PMCID: PMC7062809          DOI: 10.6515/ACS.202003_36(2).20190812C

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  25 in total

1.  Adrenal neoplasms: Effectiveness and safety of CT-guided ablation of 23 tumors in 22 patients.

Authors:  Farrah J Wolf; Damian E Dupuy; Jason T Machan; William W Mayo-Smith
Journal:  Eur J Radiol       Date:  2011-06-02       Impact factor: 3.528

2.  CT-guided radiofrequency ablation of an aldosterone-secreting primary adrenal tumor in a surgically unfit patient.

Authors:  Stephen P Johnson; Brian M Bagrosky; Erica L Mitchell; Robert C McIntyre; Nicholas G Grant
Journal:  J Vasc Interv Radiol       Date:  2008-05-27       Impact factor: 3.464

Review 3.  Prevalence of primary aldosteronism in patient's cohorts and in population-based studies--a review of the current literature.

Authors:  A Hannemann; H Wallaschofski
Journal:  Horm Metab Res       Date:  2011-12-01       Impact factor: 2.936

4.  Efficacy of radiofrequency ablation in the treatment of small functional adrenal neoplasms.

Authors:  Mishal Mendiratta-Lala; Darren D Brennan; Olga R Brook; Salomao Faintuch; Peter M Mowschenson; Robert G Sheiman; S Nahum Goldberg
Journal:  Radiology       Date:  2010-10-27       Impact factor: 11.105

5.  Radiofrequency ablation for benign aldosterone-producing adenoma: a scarless technique to an old disease.

Authors:  Shirley Yuk-Wah Liu; Enders Kwok-Wai Ng; Paul Sing-Fun Lee; Simon Kin-Hung Wong; Philip Wai-Yan Chiu; Wilfred Lik-Man Mui; Wing-Yee So; Francis Chun-Chung Chow
Journal:  Ann Surg       Date:  2010-12       Impact factor: 12.969

6.  A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.

Authors:  Gian Paolo Rossi; Giampaolo Bernini; Chiara Caliumi; Giovambattista Desideri; Bruno Fabris; Claudio Ferri; Chiara Ganzaroli; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Massimo Mannelli; Mee-Jung Mattarello; Angelica Moretti; Gaetana Palumbo; Gabriele Parenti; Enzo Porteri; Andrea Semplicini; Damiano Rizzoni; Ermanno Rossi; Marco Boscaro; Achille Cesare Pessina; Franco Mantero
Journal:  J Am Coll Cardiol       Date:  2006-11-13       Impact factor: 24.094

7.  Predictors of successful outcome after adrenalectomy for primary aldosteronism.

Authors:  Wei Wang; WeiLie Hu; XiaoMing Zhang; BangQi Wang; Chen Bin; Hai Huang
Journal:  Int Surg       Date:  2012 Apr-Jun

8.  Radiofrequency ablation compared with laparoscopic adrenalectomy for aldosterone-producing adenoma.

Authors:  S Y Liu; C M Chu; A P Kong; S K Wong; P W Chiu; F C Chow; E K Ng
Journal:  Br J Surg       Date:  2016-08-11       Impact factor: 6.939

9.  Outcome of patients undergoing laparoscopic adrenalectomy for primary hyperaldosteronism.

Authors:  Brian K P Goh; Yeh-Hong Tan; Sidney K H Yip; Peter H K Eng; Christopher W S Cheng
Journal:  JSLS       Date:  2004 Oct-Dec       Impact factor: 2.172

10.  Safety and Efficacy of Epicardial Ablation of Ventricular Tachyarrhythmias: Experience from a Tertiary Referral Center in Taiwan.

Authors:  Chin-Yu Lin; Fa-Po Chung; Yenn-Jiang Lin; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Jo-Nan Liao; Ta-Chuan Tuan; Tze-Fan Chao; Yao-Ting Chang; Yun-Yu Chen; Abigail Louise D Te; Shinya Yamada; Shih-Ann Chen
Journal:  Acta Cardiol Sin       Date:  2018-01       Impact factor: 2.672

View more
  2 in total

Review 1.  Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation.

Authors:  Byung Kwan Park; Masashi Fujimori; Shu-Huei Shen; Uei Pua
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-01

2.  Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study.

Authors:  Béatrice Bouhanick; Marie C Delchier; Séverine Lagarde; Romain Boulestreau; Claude Conil; Philippe Gosse; Hervé Rousseau; Benoit Lepage; Pascale Olivier; Panteleimon Papadopoulos; Hervé Trillaud; Antoine Cremer
Journal:  J Hypertens       Date:  2021-04-01       Impact factor: 4.776

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.